Author: Chang-Monteagudo, A.; Ochoa-Azze, R.; Climent-Ruiz, Y.; Macias-Abraham, C.; Rodriguez-Noda, L.; Valenzuela-Silva, C.; Sanchez-Ramirez, B.; Perez-Nicado, R.; Gonzalez-Mugica, R.; Hernandez-Garcia, T.; Orosa-Vazquez, I.; Diaz-Hernandez, M.; Garcia-Garcia, M. d. l. A.; Jerez-Barcelo, Y.; Triana-Marrero, Y.; Ruiz-Villegas, L.; Rodriguez-Prieto, L.; Puga-Gomez, R.; Guerra-Chaviano, P. P.; Zuniga-Rosales, Y.; Marcheco-Teruel, B.; Rodriguez-Acosta, M.; Noa-Romero, E.; Enriquez-Puertas, J.; Porto-Gonzalez, D.; Leon-Monzon, K.; Chen, G.-W.; Herrera Martinez, L.; Valdes-Balbin, Y.; Garcia-Rivera, D.; Ve,
Title: A single dose of SARS CoV 2 FINLAY FR 1A dimeric RBD recombinant vaccine enhances neutralization response in COVID19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial Cord-id: i5rcdhs8 Document date: 2021_3_3
ID: i5rcdhs8
Snippet: We evaluated response to a single dose of the FINLAY FR 1A recombinant dimeric RBD base vaccine during a phase I clinical trial with 30 COVID 19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination for all participants, similar to that previously found during vaccination of naive individuals; b) a single dose of vaccine induces a 20 fold increase in antibody response one week after vaccination and r
Document: We evaluated response to a single dose of the FINLAY FR 1A recombinant dimeric RBD base vaccine during a phase I clinical trial with 30 COVID 19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination for all participants, similar to that previously found during vaccination of naive individuals; b) a single dose of vaccine induces a 20 fold increase in antibody response one week after vaccination and remarkably 4 fold higher virus neutralization compared to the median obtained for Cuban convalescent serum panel. These preliminary results prompt initiation of a phase II trial in order to establish a general vaccination protocol for convalescents.
Search related documents:
Co phrase search for related documents- active surveillance and liver kidney: 1
- active surveillance and local pain: 1, 2, 3
- active surveillance and local site: 1
- activity limitation and acute disease: 1
- acute disease and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute disease and local event: 1
- acute disease and local pain: 1, 2, 3, 4
- acute disease and local site: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date